Contineum Therapeutics Outperforms Medical Peers This Year

Contineum Therapeutics, Inc. (CTNM) is outperforming the Medical sector this year, with a 33.1% year-to-date return compared to the sector's 3.5% average. CTNM has a Zacks Rank of #2 (Buy) and its full-year earnings estimate has increased 11.5% over the past three months. The company belongs to the Medical - Biomedical and Genetics industry, which has gained 19.4% this year.